Industrial bioscience company Amyris has entered into a research agreement with a commercial license option with Janssen Biotech. Under the terms of the agreement, facilitated by Johnson & Johnson Innovation, the collaboration will use Amyris’s µPharm platform technology to develop a customized library of natural and natural-like compounds to test against Janssen’s therapeutic target. Amyris’s µPharm platform technology enables an integrated discovery and production process for therapeuti...